Stargardt disease pipeline shifts as Belite Bio clears enrollment risk for tinlarebant
Discover why Belite Bio’s DRAGON II enrollment milestone shifts Stargardt disease drug development and what it means for investors and regulators.
Why pinguecula drug development is gaining momentum after Cloudbreak Pharma’s FDA discussions
Find out why Cloudbreak Pharma’s FDA discussions are changing how investors and regulators view pinguecula drug development and late-stage ophthalmology risk.
Can Greenlane Holdings Inc. turn Berachain’s HONEY collateral expansion into a credible digital asset treasury signal?
Find out how Greenlane Holdings Inc. is linking its digital asset treasury strategy to Berachain’s evolving stablecoin liquidity model and what it means for investors.
How Rezolve Ai is aligning its platform strategy with fast-forming agentic commerce standards shaping AI-led retail (NASDAQ: RZLV)
Agentic commerce standards are forming faster than expected. Find out how Rezolve Ai is positioning its checkout platform at the center of AI-driven transactions.
What Cognizant’s expanded role inside Kohler reveals about the future of AI-led industrial transformation (NASDAQ: CTSH)
Discover how Cognizant Technology Solutions and Kohler Co. are reshaping enterprise AI and cloud strategy through a deeper, long-term partnership.
What GCT Semiconductor Holding Inc.’s satellite deal reveals about the next phase of global 5G networks
Find out how GCT Semiconductor Holding Inc.’s satellite licensing deal could reshape 5G connectivity economics and open new growth pathways.
What the end of the Kowa partnership signals for Arcutis Biotherapeutics’ commercial control of ZORYVE
Arcutis Biotherapeutics ends its Kowa partnership and takes full control of ZORYVE promotion. Find out what this signals for adoption and strategy.
VSE Corporation’s Precision Aviation Group acquisition reshapes competitive dynamics in the global aviation aftermarket (NASDAQ: VSEC)
Find out how VSE Corporation’s $2 billion Precision Aviation Group acquisition could reshape aviation aftermarket margins and competitive dynamics.
Inside Ares Management Corporation’s $1.6bn bet on Evermark and the future of mass-market beauty brands
Ares Management Corporation leads $1.6 billion financing for Evermark. Find out how private credit is reshaping consumer brand consolidation.
Why Kadant is expanding its European industrial footprint through the voestalpine BÖHLER Profil deal (NYSE: KAI)
Kadant is acquiring voestalpine BÖHLER Profil to deepen its industrial processing strategy. Find out what this deal signals for investors and competitors.